About Foamix

Foamix Pharmaceuticals is a specialty pharmaceutical company, developing innovative solutions for the field of dermatology.
  
The company is in late-stage clinical development of two lead products based on the company’s first-in-class topical Minocycline Foam: FMX101, for the treatment of moderate-to-severe acne, and FMX102, for the treatment of impetigo.
  
Having completed Phase II clinical trials of these product candidates, the company expects to initiate Phase III pivotal clinical trials for both in 2015.
Read More

Minocycline Foam

We are developing a topical formulation of minocycline utilizing our proprietary foam technology platform. Our development program consists of three potential indications that we are pursuing: moderate-to-severe acne, impetigo, and rosacea. 
  
Our phase II results of minocycline foam 4%, applied once-daily, for the treatment of moderate-to-severe acne, showed greater than a 70% reduction in inflammatory acne lesions. We intend to commence Phase III trials for minocycline foam 4% in the United States in 2015

 

Read More

Recent News

Nov 14

Foamix Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014 

Read more...
Nov 13

Foamix Announces Two New U.S. Patents Relating To Topical Tetracycline Compositions 

Read more...
Nov 11

Foamix Pharmaceuticals Third Quarter 2014 Conference Call & Webcast Scheduled for Monday, November 17, 2014 

Read more...